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Il mio progetto di dottorato, presentato in questo lavoro di tesi, è stato 
focalizzato sul settaggio di un modello animale di artrite/osteomielite mediate da 
Staphylococcus aureus, che nell’uomo è il batterio maggiormente responsabile 
di queste gravi e debilitanti patologie. Queste malattie sono difficili da trattare 
anche per la costante crescita di Stafilococchi multi resistenti agli antibiotici 
(MRSA) e attualmente nessun vaccino contro questo batterio è disponibile sul 
mercato.  
Il modello settato è riproducibile e duraturo e mima ciò che avviene nell’uomo, 
con le due classiche fasi di infezione: la fase acuta e quella cronica. Nel 
presente lavoro è stata studiata la risposta immunitaria dell’ospite durante tutte 
le fasi della patologia, sia considerando ciò che avviene nel sito di interesse 
(articolazioni del ginocchio) sia la situazione sistemica. 
Questo modello è stato inoltre utilizzato per testare l’efficacia di un vaccino 
contro S. aureus proposto da Novartis. 
I risultati di tale studio sono riportati nella seguente tesi. 
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       1 Introduction 
1.1 Staphylococcus aureus 
Staphylococcus was first isolated in 1880 in United Kingdom, by the 
surgeon Sir Alexander Ogston in pus from a surgical abscess in a 
knee joint (1). Staphylococcus aureus is a facultative anaerobic 
Gram-positive coccus, member of the Firmicutes, also known as 
"golden staph" and “Oro staphira”. S. aureus appears as grape-like 
clusters when observed through a microscope, and it has large, 
round, golden-yellow colonies, often surrounded by a hemolytic halo, 
when grown on blood agar plates (2). 
S. aureus is the most prevalent specie of staphylococci that leads 
Staph-mediated infections. It frequently colonizes different body 
districts such as nares, axilla, vagina, pharynx and skin.  It has been 
reported that 20% of the human population are long-term carriers of 
S. aureus and worldwide approximately 30-50% of the healthy adults 
are colonized at any time point during their life (3). 
Although S. aureus is not always pathogenic, S. aureus disease-
associated strains are often able to promote infections by, for 
example, producing potent protein toxins, and expressing cell-
surface proteins that bind and inactivate antibodies (4, 5).  
Methicillin-resistant Staphylococcus aureus (MRSA) resistant strains 
have become resistant to most widely used β-lactam antibiotics. 
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MRSA strains are most often found associated with institutions such 
as hospitals, but are also becoming very common in community-
acquired infections (6).  
There are many clinical manifestations of staphylococcal infections, 
ranging from skin and soft tissues diseases to the most invasive 
pathologies represented by the metastatic infections and endocarditis 
(7, 8, 9, 10, 11). 
In most cases infections occur after breaches of the skin or mucosal 
barriers through wounds, trauma or surgical intervention that allow 
the organism to access the tissues or the bloodstream; once the skin 
or mucosa have been penetrated, the infection may spread to the 
blood causing invasive diseases. Figure 1 reports the different 
staphylococcal diseases, arranged on the basis of their frequency 
and severity (12). 
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Figure 1: S. aureus diseases 
The pyramid reports the broad spectrum of Staphylococcus aureus 
diseases. The severity of them decreases from top to bottom, on the other 
end the frequency decreases from bottom to top. 
Adapted from “Strategies for and advances in the development of 
Staphylococcus aureus prophylactic vaccines”; Jane Broughan et al. 2011 
 
      1.2 Staphylococcus aureus joints and bones infections 
Staphylococci are the principal causative agents of two major types 
of bones infections, septic arthritis and osteomyelitis, which involve 
the inflammatory destruction of joints and bones. These diseases 
lead serious morbidity and are often difficult to treat (13). The most 
common routes of infection for both septic arthritis and osteomyelitis 
are either haematogenous, resulting from bacteremia, contiguous, 
when the infection is transmitted from local tissue, or direct, resulting 
from infiltration of bone, often following surgeries, injuries, or 
implantations of a foreign body, for example joint replacement (13, 
10 
 
14, 15, 16, 17). Among the possible routes of infection  most septic 
joints develop as a result of hematogenous seeding of the vascular 
synovial membrane due to a bacteremic episode (18,19). Infections 
may result in acute or chronic forms and affect native joints, 
especially knee and hip, or prosthetic joints, long bones, vertebrae 
and almost any other bone. The incidence of septic arthritis is 
between 2 and 10 in 100,000 in the general population but it may be 
as high as 30–70 per 100,000 in rheumatoid arthritis sufferers or 
recipients of prosthetic joints (15, 20, 21) and it is more common in 
children than adults, and in males than in females (22). 
Haematogenous osteomyelitis usually effects children and elderly 
people (17) and in children the incidence is between 1 in 5000 and 1 
in 10,000 (23). Local spread of infection from contiguous tissue to 
bone or direct infection can occur at any age, with foreign body 
implants representing an important risk factor (17). The presence of 
an implant is frequently associated with chronic osteomyelitis, where 
antibiotic treatment is often ineffective, and removal of the implant 
and debridement are required (14). Some cases of relapsing 
osteomyelitis with several decades between subsequent episodes 
have been documented, and there are records of reactivation fifty or 
even eighty years after the first infection (14, 24, 25). 
Staphylococcus, principally S. aureus, accounts for between 37% 
and 67% of septic arthritis isolates as resulting from studies carried 
out in a range of nations (15, 26, 27, 28).   
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Figure 2: Knee joint anatomy 
From:http://www.practical-wellness-guide.com/physical/total-personal-
health-care-and-wellness 
 
Septic arthritis is a joint pathology characterized by bacterial 
colonization and fast articular destruction (22). Inflammation with 
infiltration of leukocytes into the joint fluid is the result of bacterial 
growth within the synovium (15, 20). The production of bacterial 
toxins, host matrix metalloproteinases (MMPs) and reactive oxygen 
species and lysosomal enzymes, promote the destruction of 
cartilage. This latter process, mediated by polymorphonuclear 
leukocytes, begins with degradation of host proteoglycans followed 
by collagen breakdown within a few hours after the infection. The 
containment of the inflammation within the joint results in increasing 
pressure which prevents blood and nutrient supply to the joint 
increasing joint damage (15, 20, 29, 30). 
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Osteomyelitis includes a range of infections in which bacteria 
colonize bone with associated inflammation and bone destruction. 
Acute osteomyelitic foci are characterized by pus-forming 
inflammation at the site of microbial colonization. Damage to bone 
matrix, compression and destruction of vasculature is also observed 
as the infection spreads to surrounding soft tissues, which can further 
exacerbate bone necrosis (16, 17). Sections of dead bone, known as 
sequestra, may then detach resulting in separate infectious foci 
which, due to the lack of vasculature, are protected from immune 
cells and antibiotics (16,17). Such areas of dead, infected tissues 
that are inaccessible to the immune response or antimicrobials can 
lead to chronicization of the infection (16). 
The infection by S. aureus is accompanied by a rapid recruitment of 
polymorphonuclear granulocytes and activated macrophages that are 
then followed by T cells. Although monocytes and macrophages are 
important to clear bacteria, they also play a pivotal role in the 
destructive inflammation within the joint (13). Moreover, a number of 
host cytokines play a significant role in the pathogenesis of 
osteomyelitis and arthritis, and there is strong evidence that 
production of these cytokines is induced by staphylococcal infection 
of bone and joints, and that they directly contribute to bone 
destruction. In particular, the inflammatory cytokines tumor necrosis 
factor α (TNFα), interleukin 1 (IL-1) and IL-6 seem to be especially 
important in bone physiology and pathology (32). In patients with 
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acute osteomyelitis, plasma levels of TNFα, IL-1β (the secreted form 
of IL-1) and IL-6 are all elevated (32, 33). High levels of IL-1β, IL-6 
and TNFα are also found in the synovial fluid of patients with septic 
arthritis (34, 35). The local source of these cytokines is not fully 
understood. Production of IL-1β can be induced in human osteoblast-
like cell lines by a variety of stimuli, including TNFα (36). Infiltrating 
immune cells may therefore be a more likely source of IL-1β and 
TNFα in bone in response to infection (37, 38, 39, 40). Moreover IL-6 
is produced by osteoblasts in response to a variety of signals, 
including infection with S. aureus (37, 38). In addition to 
staphylococcal induction of inflammatory mediators that modulate the 
actions of osteoblasts and osteoclasts, bacteria of this genus are 
involved in more direct interactions with bone cells. Invasion and 
persistence of S. aureus in ‘non-professional phagocytic’ host cells in 
vitro has been described for many different cell types, including 
epithelial cells, endothelial cells and keratinocytes (41, 42). Electron 
microscopy has demonstrated the presence of bacteria within 
osteoblasts and osteocytes of embryonic chicks following injection 
with S. aureus, indicating that internalization by bone cells could also 
occur in vivo (43). The internalization of S. aureus by bone cells in 
vivo provides a protective niche for the bacterium, where it is 
shielded from immune effector mechanisms and antibiotics may help 
to explain persistent cases of osteomyelitis. Increasing evidence 
supports the importance of staphylococcal surface components as 
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virulence determinants by enabling initial colonization. In a number of 
studies, mutations in these surface receptors strongly reduced the 
ability of staphylococci to produce infection. In a murine septic 
arthritis model, inoculation of mice with a strain mutated in the 
collagen adhesin gene showed that septic arthritis occurred 43% less 
often than in the corresponding wild type (44). Also vaccination with a 
recombinant fragment of the S. aureus collagen adhesin was able to 
reduce the sepsis-induced mortality rate to 13%, compared to 87% of 
the control group (45). Nevertheless, the role of collagen adhesion of 
S. aureus as a major virulence factor has recently been questioned 
since approximately 30 to 60% of clinical isolates do not display 
collagen binding in vitro or the cna-encoded collagen adhesin (46). 
Staphyloccal fibronectin binding proteins (FbpA and FbpB) may also 
play a major role in the colonization and virulence of septic arthritis. 
In a recent study all the tested clinical isolates (n = 163) contained 
one or both of the coding regions for these binding proteins and 95% 
of these strains had a comparable fibronectin binding capacity to that 
seen in a staphylococcal reference strain known to efficiently bind 
fibronectin (47). These receptors may play an additional role in an 
intracellular immune-avoidance strategy. S. aureus survives 
intracellularly after internalization by cultured osteoblasts (48). Initial 
adherence to cells is mediated by S. aureus fibronectin receptors 
(49) possibly using fibronectin as a bridge between the host cell and 
the bacterial receptors. Following adherence, bacteria may be 
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internalized by host mechanisms involving membrane pseudopod 
formation (seen in established bovine mammary epithelial cell lines) 
or through receptor-mediated endocytosis via clathrin-coated pits 
(seen in mouse osteoblasts and epithelial cells, 49, 50). 
Following internalization, staphylococci may induce apoptosis via a 
host caspase-dependent mechanism or survive intracellularly (49, 
51, 52, 53). Induced apoptosis may exacerbate the host cell damage 
seen in septic arthritis. Moreover, staphylococci may escape 
clearance by the immune system and antimicrobial therapy by 
persisting within these host cells. This survival was recently 
demonstrated in vivo when S. aureus cells were found in the 
cytoplasm of embryonic chicken osteoblasts and osteocytes in 
mineralized bone matrix (43). In another study, S. aureus was found 
within polymorphonuclear neutrophils in an infection model, and 
these infected host cells were able to establish infection in naïve 
animals (54). Therefore, this pathogen may utilize invasion as an 
immune avoidance technique during the host inflammatory response. 
Following the down regulation of the adaptive immune response 
through T-cell apoptosis (mediated by superantigens, other toxins, 
and invasion), fulminant and/or persistent infection may result. 
Antibiotic therapy during septic arthritis is efficacious only when 
rapidly applied and, often, in combination with joint drainage (29). 
The antibiotic therapy is based on appropriate culture and antibiotic 
sensitivity results (55). 
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Osteomyelitis, on the contrary, results often refractory to antibiotic 
treatment, a problem exacerbated by the increasing levels of 
antibiotic resistance among Staphylococcus spp. This is further 
complicated by the emergence of particularly persistent, antibiotic-
resistant ‘small colony variant’ forms that may be selected for by 
certain current treatment regimens (14, 56, 57). Staphylococcal bone 
infections are thus likely to be a continuing and probably increasing 
problem, and the understanding of host-pathogen interactions in 
bones and joints will become crucial for the development of novel 
therapeutic and preventing strategies.  
1.3 Novartis proposed Combo vaccine  
The treatment of staphylococcal infections in the last years has been 
complicated also by the emergence of multidrug resistant strains, 
which can cause invasive diseases that frequently lead to death. 
Presently,no vaccines are available to prevent this kind of infections. 
Novartis Vaccines & Diagnostic (NVD) has engaged in the research 
and development of an effective vaccine against S. aureus infections. 
Using different approaches, including reverse vaccinology, proteomic 
and comparative genomics analyses (58), Novartis selected a 
combination of four highly conserved antigens, which were proposed 
as components of a potential innovative multiprotein-based vaccine. 
The vaccine formulation is composed of two surface proteins FhuD2, 
and Sur 2, and three secreted proteins, a toxoid derivative of -
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Hemolysin (Hla) (H35L) and EsxA-B, a fusion protein of two secreted 
toxins. 
Hla is a pore-forming toxin whose expression is associated with 
staphylococcal pneumonia in mice and humans (59). Its expression 
is up-regulated in exponential phase and consistently expressed by 
clinically relevant strains. The protein included in the vaccine carries 
a substitution of histidine 35 with leucine that produced a mutant 
toxin (H35L) without hemolytic or lethal activity (60). EsxA-B derives 
from the fusion of the proteins EsxA and EsxB, both of them being 
expressed by clinically relevant strains and involved in abscess 
formation (61). FhuD2 is a lipoprotein involved in iron uptake, up 
regulated in iron deplete-conditions (58). Finally Sur 2 is a protein of 
still unknown function. This antigen combination has been tested 
using different animal models of S. aureus infections (pneumonia, 
abscess and sepsis model), resulting protective in all the cases and 
effective in preventing the infections carried out by different S. aureus 
strains. 
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1.4 Aim of the project  
Since the relative importance of S.aureus mediated joints and bones 
infections both in terms of frequency and severity (fig. 1), the aim of 
this work was the development of an animal model of septic 
arthrosynovitis and osteomyelitis resembling the natural disease in 
humans and suitable for testing preventive and therapeutic tools. The 
hematogenous source of infection (intravenous inoculation) was 
preferred among the others due to its higher frequency of occurrence 
in humans. Our attention was focused to track in the long term 
bacterial infiltration in joints and bones using different microbiological 
and histopathological tools, which could allow us to have a complete 
overview of the situation and to understand the mechanisms set up 
by the host to contain or eradicate bacterial infection.   Antibodies 
response, cytokines profiles during the time and cellular recruitment 
were therefore monitored for a period that allowed us studying both 
acute and chronic phases of these diseases in situ. The systemic 
infection and the host immune response were also evaluated. Finally 
the Novartis proposed vaccine against S. aureus diseases was 
tested in the model of acute infection, and bacterial reduction in situ 
and systemically was evaluated and compared to a standard 
antibiotic prophylaxis.   
Having a powerful tool to study specific bacterial mediated diseases 
is nowadays an important requirement for the scientific community to 
shed light on the complex interactions between host and pathogens 
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and to test treatments for preventing or contrasting infections. We 
believe that our work could improve the knowledge in the field of S. 
aureus dependent pathologies, opening the possibility for further 
investigations in several fields of study. 
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2 Results 
2.1 S. aureus shows a particular tropism for bones and 
joints causing both arthrosynovitis and osteomyelitis 
in mice 
Since S. aureus was demonstrated to have a particular tropism for 
bones and joints in humans during natural infections (13), we started 
analyzing the interaction between pathogen and host infecting mice 
with bioluminescent bacteria. Bioluminescence (BLI) has been used 
as a powerful tool for studying host-pathogen interactions for years 
(62) and nowadays many different S. aureus bioluminescent strains 
are available on the market (Perkin Elmer). Many of them were 
generated using a plasmid (pXEN5, Perkin Elmer) carrying the 
Photorhabdus luminescens lux operon (figure 3), which allows 
random integration of lux genes into either the bacterial chromosome 
or natural plasmids carried by the pathogen. Once integrated in 
bacterial DNA  downstream of a functional promoter, this operon is 
able to  make bacteria bioluminescent without the need of extra 
sources of substrates (fig.3). The lux operon is a 9-kilobase fragment 
of the Photorhabdus luminescens genome that controls 
bioluminescence through the catalyzation of the enzyme luciferase 
(Meighen, 1991). The lux operon has a known gene sequence of 
luxCDAB(F)E, where lux A and lux B code for the components of 
luciferase, and the lux CDE codes for a fatty acid reductase complex 
21 
 
that makes the fatty acids necessary for the luciferase mechanism 
(63). Lux C codes for the enzyme acyl-reductase, lux D codes for 
acyl-transferase, and lux E makes the proteins needed for the 
enzyme acyl-protein synthetase. Luciferase produces blue/green 
light through the oxidation of reduced flavin mononucleotide and a 
long-chain aldehyde by diatomic oxygen. The reaction is summarized 
below (Silverman et al., 1984): FMNH2+O2+R-CHO → FMN + R-
COOH + H2O + Light.  
 
Figure 3. Generation of bioluminescent bacteria using the pXEN5 
random integration system. pXEN5 plasmid used for random integration 
of Photorhabdus luminescens lux operon in DNA of recipient bacteria and 
mechanism of action of the inserted lux operon. luxA-E are lux genes, Kan 
is the resistance for the antibiotic kanamycin. 
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The light produced by this enzymatic reactions is captured by special 
imaging systems, in our case IVIS100 and IVIS Spectrum-CT, which 
exploit a special cooled camera enclosed in a light-proof box to 
capture all the photons emitted by the live mouse. Bioluminescent 
spots from the mouse body can be related to specific body areas and 
the intensity of the light emitted can be quantified.  
The bioluminescent strains we used and their features in term of 
integration are reported here below in figure 4. 
 
Figure 4. List of bioluminescent S. aureus used for in vivo imaging 
studies. Parenteral strains are reported in the brackets and whether the lux 
operon was inserted inside the chromosome or into a stable native plasmid 
is reported on the right. 
 
All the strains used were highly bioluminescent and suitable for in 
vivo studies, as reported in the site 
http://www.perkinelmer.com/Catalog/Family/ID/Gram%20Positive.  
S. aureus bioluminescent strains were therefore used to infect mice 
in the lateral tail vein (i.v.) and infection progression was followed for 
at least 1 week after the injection using an IVIS 100® machine 
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(Perkin Elmer). The i.v. route of infection was chosen trying to mimic 
a hematogenous source of infection, often occurring in humans. As 
reported in figure 5A, 1 day after injection S. aureus reached the 
knee joints being able to establish a local infection that persisted for 
at least 7 days. Bioluminescence values, expressed as 
photon/second, (p/s) were calculated considering only our region of 
interest (ROI) reported as red circle in figure 5A, and a very good 
correlation could be observed when BLI was compared to colony 
forming units (CFUs) counted after knee joint washes the last day of 
the experiment (fig. 5B). Similarly to what obtained for Xen 36 strain, 
when other S. aureus strains were used to infect animals (fig. 5C) 
bacteria rapidly and lastingly localized in the joints, underlying that all 
the different S. aureus strains we tested had the ability to reach this 
body district. Finally we confirmed the presence of bacteria in knee 
joints after i.v. inoculation using confocal microscopy, as reported in 
figure 5D. 
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Figure 5. Staphylococcus aureus showed a particular tropism for 
joints in a mouse model of intravenous infection. A) Bioluminescence 
observed during the time from day 0 through day 7 in mice intravenously 
infected with S. aureus Xen 36 strain (1x107 CFU/mouse). In red, Region 
Of Interest (ROI) used to quantify the signal. B) A good correlation 
expressed as Spearman R value was measured when bioluminescence in 
the selected ROIs was compared to CFU recovered in knee joint washes of 
animals infected with Xen 36 strain. C) Signals observed at different time 
points using 3 S. aureus bioluminescent strains commercially available. S. 
aureus tended to localize in joints. D) Confocal microscopy analysis of a 
mouse knee from an infected animal. In yellow: bone (osteocalcin), in red: 
muscle (phalloidin), in blue: nuclei (dapi), in green: S. aureus 
 
Since in humans S. aureus is able to cause osteomyelitis, we used 
the in vivo imaging approach also to better understand whether 
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bacteria which had reached the joint could invade the bone tissue. 
Mice were again i.v. infected with the highly bioluminescent strain 
Xen 36 and then followed for 1 week post infection. Using the IVIS 
spectrum-CT system®  which combines a camera able to acquire 
bioluminescent signals and a tomography system that can scan 
sections of the animal body, we found that bioluminescent bacteria 
were not only present in the knee joint area but also in the tibia. This 
is shown in figure 6 where the 2D (A) and the 3D (B) analysis of the 
same infected animal are reported.  
 
Figure 6.Staphylococcus aureus was localized both in knee joints and 
bones. A) 2D bioluminescent acquisition of a CD1 mouse i.v. infected with 
Xen 36 S. aureus strain. Two bioluminescent signals were detected in the 
left leg. B) 3D analysis of the same animal. The 2 bioluminescent signals 
turned to be one in the knee joint and the other in the left tibia. In both the 
cases an IVIS spectrum-CT system® was used to acquire images. 
 
These findings allowed us to confirm that S. aureus-mediated 
hematogenous infection could cause arthrosynovitis and 
osteomyelitis, nevertheless, to better characterize bacterial 
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localization and local damages we carried out histopathological 
analysis of tissues obtained from infected mice.  One week after 
infection with S. aureus Newman strain, mice were sacrificed, knees 
were removed, fixed and tissue slices were prepared. Hematoxylin 
and Eosin (H&E) staining were performed and histopathological 
analysis of these preparations was compared to slices derived from 
joints and bones of not infected mice. As shown in figure 7A on the 
right (red-framed image), when animals were infected with S. aureus 
the normal architecture of bones and joints was effaced by the 
presence of mixed inflammatory cells (with prevalence of neutrophils 
and macrophages) as compared with a control animal on the left 
(black-framed image). In particular, the tibia was destroyed and 
granulomas/abscesses were observed. Periostal inflammation was 
severe, causing thickening of the periostal tissue. Inflammation was 
evident in the synovia, which appeared severely thickened. In the 
enlargement, elongated cells can be seen which formed a wall 
around foci of inflammation composed by neutrophils and 
macrophages. Within the inflammatory focus, clusters of bright pick 
eosinophylic slightly hyaline material consistent with the presence of 
bacteria were observed. Indeed, immune-histochemical staining 
demonstrated that S. aureus was present in bone abscesses (figure 
7B_1) and a wall of neutrophils was built up all around these 
structures (fig. 7B_3). 
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Figure 7.Staphylococcus aureus was responsible for causing 
arthritis and osteomyelitis in mice. A) Hematoxylin and Eosin (H&E) 
staining of mouse legs i.v. infected with S. aureus Newman strain. On 
the left (surrounded with a black frame) a slice from a not infected 
animal is reported as negative control, while on the right (red frame) a 
slice from a mouse infected and sacrificed 1 week after injection is 
reported. F= Femur T= Tibia. The smallest panel is an enlargement of a 
specific area of the red-frame image. B) Immune-histochemistry staining 
of knees from animals treated intravenously with S. aureus. In B1) S. 
aureus was stained in red (this antibody recognizes soluble and 
structural antigens of Staphylococcus aureus whole bacterium) in B3) 
neutrophils were marked in violet (the antibody recognizes a currently 
undetermined structure on the neutrophil membrane). B2) is the isotype 
control of B3.  
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  2.2 Setting up of an arthrosynovitis mouse model  
        of  infection suitable for long lasting in vivo studies 
 
2.2_1 CFU counts and histological analysis  
For the setting up of a long lasting and reproducible mouse model of 
hematogenous S. aureus-mediated arthrosynovitis Xen 36 did not 
appear to be a suitable strain. In fact, the infectious dose required to 
be able to follow in vivo a detectable bioluminescent signal was too 
high and mice showed several signs of disease after the first week 
from the infection. The S. aureus Newman strain was therefore 
chosen for these experiments since it has been largely used in 
research worldwide being well adapted for animal studies. The first 
objective was to find a dose high enough to homogeneously infect a 
group of mice both systemically and in the knee joints, but reducing 
the risk of causing severe disease and/or death.   
Immediately after the infection, S. aureus disappeared from the blood 
and rapidly disseminated in all the organs (64). In particular, the most 
infected organs were the kidneys, as illustrated in figure 8, which 
were therefore chosen as markers for systemic infection. 
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Figure 8. Staphylococcus aureus intravenously injected in CD1 mice 
reached all organs. CFU counts in organs 4 days after intravenous 
administration of about 1x107CFU/mouse of S. aureus Newman strain. 
CFU were normalized among different organs reporting the total colonies 
counted in that organ. 
 
Mice were intravenously infected with doses ranging from 1x107 to 
1x104 CFU/mouse and followed up to 3 weeks post infection. Kidneys 
of infected animals were collected and knee joints washes were 
performed. In figure 9 we reported the results that we obtained. Mice 
treated with the dose of 1x107 showed evident signs of illness and, 
from four days after the infection, they started dying, while doses as 
low 1x105-1x104 resulted in poor or even absent infection. For these 
reasons a dose of 1x106 was chosen for our purposes since no 
animal died during this observation period and all of them resulted 
significantly infected both systemically and locally.  
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Figure 9. The dose of 1X106 CFU/mouse was used to establish a long 
lasting and reproducible model of arthrosynovitis in mice. A) CFU 
counts in knee joints washes of CD1 mice intravenously infected with S. 
aureus Newman strain. Animals were infected with different doses from 
1x107 to 1x104 CFU/mouse and then sacrificed at day 4, and 1, 2 and 3 
weeks after injection. Single dots represented single animals and different 
colors were used for the different doses. B) CFU counts in kidneys of mice 
infected i.v. with Newman strain. Doses ranging from 1x107 to 1x104 
CFU/mouse were used and animals were sacrifice 4 days, 1, 2 and 3 
weeks after injection. Single dots represented single animals and different 
colors were used for the different doses. 
 
After this preliminary experiment, we inoculated animals with 106 
CFUs and we followed the progression of S. aureus dissemination up 
to 90 days after the infection. Also in this case CFU counts in kidneys 
were used as marker of systemic infection and CFU counts in joint 
washes as marker of local infection in the knees joints. We 
additionally measured CFUs in the blood as a possible second 
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marker of systemic infection since it had been reported that during 
the chronicization of the pathology S. aureus could escape from the 
organs ad exploit the bloodstream for further spreading (64)  
As reported in figure 10, the peak of the infection seemed to be 
reached between 1 and 2 weeks after the inoculum when CFUs 
recovered in joints and kidneys were maximal (fig.10 A-B). Starting 
from 1 month after infection, the CFUs started to decrease both in 
kidneys and in knee joints as the infection was being controlled by 
the host to a certain extent. On the other hand, CFUs in the blood 
seemed to increase during time reaching the highest level at the 
latest time point 90 days after infection (fig.10 C). Some animals 
actually died during the experiments not always showing evident 
signs of disease. In particular, 2 out of 24 died between day 15 and 
day 30 and 4 out of 18 died between day 30 and day 90. 
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Figure 10. Bacteria could be detected up to 90 days after infection in 
knee joints, kidneys and blood. A-B-C) Logarithmic scale of bacterial 
titers in knee joint (A) kidneys (B) and blood (C) were determined at 
indicated time points. Each point represents the median and the bars 
reported the interquartile range. 
 
To better understand whether the infection was being controlled or 
was becoming chronic, we performed H&E staining of slices from 
knee joints of infected mice up to 90 days post intravenous infection. 
In figure 11 we reported the results of our observations expressed in 
terms of severity and chronicization (age-grade) of all samples 
analyzed. These analyses demonstrated that after intravenous 
infection with S. aureus, mice developed arthrosynovitis and 
osteomyelitis and that both an acute (7-14 days) and a sub-
acute/chronic (90 days) phase could be clearly detected. 
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Figure 11. Intravenous infection with S. aureus resulted in an initial 
acute phase that finally chronicized. A-B) Severity (A) and age grade (B) 
of arthrosynovitis and osteomyelitis during the time. A specific score 
(indicated in the tables) was assigned for severity and age grade of the 
disease for each knee slides analyzed at each time point. Six mice for time 
point were analyzed and medians plus interquartile range were reported.  
 
 
         2.2_2 Serological analysis 
The humoral response during the time both in situ and systemically 
was also analyzed. IgM and IgG against alpha-hemolysin (Hla), one 
of the most important and highly immunogenic virulence factors of S. 
aureus, were titrated both in sera and in the joint washes of infected 
mice at each time point as marker of infection progression. 
Anti-Hla IgM peaked seven days after the bacterial injection both in 
the knee joints and in the serum, while IgG level reached the 
maximum level at 14 and 30 days after inocula  in joint and serum 
respectively, decreasing then in knee washes along with CFU 
A B 
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decrease, while remaining almost stable during the time in the sera 
of infected animals as expected (fig.12).  
 
Figure 12. IgM and IgG could be detected both in the sera and in the 
knee lavages of infected animals. A) Hla IgG (black line) and IgM (grey 
line) curves in knee joint washes of infected animals from day 0, in red and 
pink, respectively through day 90. Medians and interquartile ranges were 
reported. B) Hla IgG (black line) and IgM (grey line) curves in sera of 
infected animals from day 0 (pre-infection time) through day 90. Medians 
and interquartile ranges were reported. 
 
As cytokine secretion can be considered a reliable indicator of 
immune activation, we also assessed cytokine levels at different time 
points after infection. In order to understand if the local inflammatory 
response was specific and if differences existed with the systemic 
response, we measured cytokine levels both in the serum and 
directly in situ. The cytokines analyzed were IL-1α, IL-1β, IL2, IL-3, 
IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17, 
A B 
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eotaxin, G-CSF, GM-CSF, IFN, KC, MCP-1, MIP-1α, MIP-1β, 
RANTES and TNF-α. In the knee joints (fig.13) all the cytokines that 
increased (IL-1α, IL-1β, IL-6, IL-10, IL-12 (p40), IL-17, eotaxin, G-
CSF, GM-CSF, IFN, KC, MCP-1, MIP-1α, MIP-1β, RANTES)  in 
comparison with time 0 (not infected animals) showed a profile of 
expression that somehow correlated with the observed trend of CFU 
number variation during infection (fig. 10A). Interestingly, IL-9 and IL-
13 were the only 2 cytokines that displayed an opposite trend, 
decreasing during the time as compared to controls. Finally some of 
them did not significantly change during the time (IL-2, IL-3, IL-4, IL-
5, IL 10, IL12p70 and TNF-α).  
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Figure 13. Cytokines profile in knee joint washes of infected animals 
during the time. A panel of 23 cytokines was analyzed in knee joint 
washes. In red data obtained with negative controls (not infected animals) 
are reported. In each graph the median and interquartile ranges of one 
cytokine is reported in pg/ml. The name of the cytokine analyzed is 
reported above each graph. 
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The situation in the serum (fig. 14) was different and more 
complicated: some cytokines did not change during the time (IL-1α, 
IL-2, IL-3, IL-4, IL-9 and RANTES); others (IL-6, eotaxin and KC) 
were secreted immediately after the infection (3 days) and then 
decreased during the time, or showed a kind of bimodal behavior (IL-
1β, IFNothers increased rapidly remaining then stable (IL-5, IL-10, 
IL-12(p40), IL-12(p70), IL-13, IL-17, G-CSF, GM-CSF, MCP-1, MIP-
1β, TNF-α). MIP-1 seemed to be secreted only at the latest time 
point. 
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Figure 14. Cytokines profile in sera of infected animals during the 
time. A panel of 23 cytokines was analyzed in sera of infected mice. In red 
data obtained with negative controls (not infected animals) are reported. In 
each graph the median and interquartile ranges of one cytokine is reported 
in pg/ml. The name of the cytokine analyzed is reported above the single 
graphs. 
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Some of the cytokines found in the knee joint washes well correlated 
with the CFU recovered in that site at different time points. In 
particular, as reported in figure 15, for most of them this correlation 
could be detected 14 days after infection (IL-6, IL-12(p40), IL-13, IL-
17, G-CSF, KC, MCP-1, MIP-1β, RANTES), while for IL-12(p40) and  
MIP-1α a good correlation was found at days 30 and 90 post 
infection respectively.  
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Figure 15. Cytokines which correlate with CFU number in knee joints.  
A correlation analysis between cytokines levels and CFUs recovered in the 
knee joint of single animals was performed. In the panel only significant 
correlations are reported together with Pearson R index and statistical 
analysis for each situation. Single dots represent single animals. Each 
graph reports the name of the respective cytokine and, on the right, the 
different time points are reported.   
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       2.2_3 Cellular analysis 
We also analyzed at each time point the immune cell populations 
recruited in the knee joint space and present in the blood of infected 
animals. First we wanted to understand if and how intravenous 
infection with S. aureus could affect the immune cell composition in 
knee joint washes. In figure 16 we reported the number of live cells 
recruited in joint washes 1 week after infection with S. aureus 
Newman strain and we compared this number with that obtained 
from cells recovered in mice mock-infected with PBS alone. As 
shown in the picture, as early as 1 week post infection the immune 
cells counted in the knee joints of infected animals were almost 100 
fold higher than those recovered in uninfected mice. 
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Figure 16. The number of live cells in knee joint washes increased 
after S. aureus infection.  Live cells recovered in knee joint washes of 
control mice injected with 100 µl of PBS (blue dots) and infected mice 
injected with the same volume of 2x106 S. aureus Newman strain (red 
dots). Logarithmic scale was used to graph these data and medians line 
are aso reported. 
 
The next step was staining those cells with specific antibodies 
directed against different cellular markers to better characterize the 
multiple cell populations. Through the gating strategy reported below, 
we were able to identify neutrophils, macrophages (only in knee joint 
washes), monocytes, dendritic cells, eosinophils (only in blood), B 
cells, CD4+ and CD8+ T cells, NK cells.  
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Figure 17. Gating strategy used for the identification of immune cells 
in knee joint washes and blood. Cellular composition of knee joint 
washes and blood was analyzed using the gating strategy reported above. 
Gate edges were underlined in pink and the name of the single cell subsets 
identified using that strategy was reported above the panel or above the 
single gate. X and Y axes reported the physical or immunological 
parameter used for preparing each specific panel. Black arrows indicated 
the analysis sequence. 
 
Locally, in the knee joints (fig. 18), cells belonging to the myeloid 
lineage increased starting from three days after the infection with an 
evident peak at 1 - 2 weeks post inoculum, which recalls the 
observed bacterial profile described in figure 10A. Neutrophils were 
the most abundant population increasing up to 1000 fold as 
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compared to the basal situation, but also monocytes and 
macrophages showed a sharp increase (10-50 fold). A similar 
situation, although less evident, was observed when myeloid cells 
were stained and counted in the blood. In this case a decrement in 
eosinophils, especially immediately after infection, was observed. 
Different the behavior of lymphoid cells in situ and systemically. 
Indeed, while lymphoid cells decreased in the blood starting 3 days 
after the injection with S. aureus, they increased in the joints. 
Noteworthy, this was true for all the lineages but not for B cells that 
significantly decreased in number also in the joints. During the 
chronic phase the cellular composition both in blood and in the knee 
joint came back to the baseline level.   
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Figure 18. Immune cell analysis of mouse knee joint washes.  Absolute 
cell numbers of immune cells identified in knee joint washes of S. aureus 
infected animals and control mice. Starting from time 0 (control animals in 
red) and through all the observation period (90 days, black line and dots) 
animals were sacrificed at established time points and immune cells 
recruited in knee joints were collected and stained. In the graphs, single 
subset populations are shown as indicted in the titles. 
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Figure 19. Immune cell analysis of mouse blood.  Absolute cell number 
of immune cells per ml of blood identified in S. aureus infected animals and 
control mice. Starting from time 0 (control animals in red) throughout all the 
observation period (90 days, black line and dots) animals were sacrificed at 
established time points and immune cells in the blood were collected and 
stained. In the graphs, single subset populations are shown as indicted in 
each title.  
 
 
 
 
 
47 
 
2.3 The acute arthrosynovitis model can be used to 
test therapeutic and preventive treatments against S. 
aureus infections   
 
2.3_1 Ampicillin treatment reduced bacterial load in 
kidneys but was not efficacious in killing S. aureus in 
knee joints 
In humans antibiotics are the first and most used treatment for S. 
aureus septic arthritis and osteomyelitis (65). Nevertheless, 
sometimes they are not able to eradicate bacteria from these sites 
because of the low vascularization of bones and joints and of the 
increase of S. aureus antibiotic resistant forms. In order to investigate 
whether a classical antibiotic treatment would be able to reduce 
bacterial burden in our model, mice infected i.v. with about 2X106 
bacteria of the S. aureus Newman strain were treated i.p. with 
100µg/g weight of ampicillin 24 and 48 hours after infection, as 
reported in literature (66). Five days later they were sacrificed, 
kidneys were collected and knee joint washes were performed.  
Interestingly, a significant reduction in CFU counts was observed in 
kidneys (fig. 20A), indicating that the antibiotic treatment had some 
positive effect on the containment of the systemic infection. On the 
contrary, a CFUs reduction in knee joints (fig. 20B) was not 
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observed, which could be expected on the basis of the reported 
difficulties to successfully treat with antibiotics such localized 
infections. 
When the cell composition in knee joint washes was analyzed no 
substantial differences were observed, with the exception of B cells, 
which appeared to be more abundant in the animals treated with 
ampicillin (fig. 20C).  
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Figure 20. Mice treated with ampicillin after infection with S. aureus 
Newman strain showed reduced bacterial load in kidneys but not in 
knee joints. A) CFU counts in knee joint washes of mice intravenously 
infected with S. aureus Newman strain and treated intraperitoneally twice 
with ampicillin 100 µg/g of body weight 7 days after inoculum. Each dot 
represented data from one single animal and black lines showed median 
values. The dotted grey line stated the lower detectable value.  B) CFU 
counts in kidneys of mice intraperitoneally treated with ampicillin after being 
infected with S. aureus Newman at the dose of 2X106 CFU/mouse. Each 
dot represented one single animal and black lines showed median values. 
The dotted grey line stated the lower detectable value.  C) Immune cell 
recruitment in knee joint washes of mice infected with S. aureus, treated 
twice with ampicillin and sacrificed 7 days after bacterial inoculum. Fold 
change in respect to the normal situation (median of naïve mice for each 
cellular subset) was plotted, medians and interquartile range were shown. 
N= Neutrophils, Mo= Monocytes, Ma= Macrophages, DC= Dendritic cells, 
B= B cells, CD4+= CD4+ T cells, CD8+ =CD8+ T cells. Statistical analysis 
was performed with a Mann-Whitney t test in all the cases and only 
statistically significant differences were reported. 
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  2.3_2 The Novartis vaccine proposed against S. aureus        
infections reduced bacterial burden in joints of infected 
mice 
 
The described model of acute arthrosynovitis in mice was then used 
to test the Novartis proposed vaccine against S. aureus mediated 
infections. Novartis vaccine is a combination (called “combo”) of 4 
protective  antigens, a detoxified form of alfa-hemolysin (HlaH35L) 
where histidine 35 was mutated with a leucine, the fusion protein 
EsxA-B that consisting of the 2 extracellular secretion system 
proteins A and B both involved in infection persistence (61), the 
highly conserved ferric-hydroxamate uptake D2 (FhuD2) (58) protein, 
important in the early stages of infection and Sur 2, a surface 
lipoprotein highly conserved and still poorly characterized. Different 
groups of mice received two immunizations with a two-week interval 
either with the combo vaccine adjuvanted with aluminum hydroxide 
(alum) or the adjuvant alone as negative control. Ten days after, the 
animals were infected with about 2X106 CFU/mouse intravenously, 
they were sacrificed 7 days after and kidneys, blood, serum were 
collected together with knee joint washes to perform microbiological 
and immunological analysis. 
As shown in figures 21A and 21B, immunization with the protein 
combination resulted in a significantly lower bacterial burden both in 
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the knee joints (A) and in the kidneys (B), suggesting that, in this 
model, the efficacy of a preventive vaccine treatment may be more 
efficacious than a classical therapeutic approach in reducing S. 
aureus mediated infection in joints.  
 
Figure 21. Mice immunized with the S. aureus combo vaccine resulted 
protected against a subsequent systemic infection with S. aureus 
Newman strain. A) CFU counts in knee joint washes of mice immunized 
and intravenously infected with S. aureus Newman strain 7 days after 
inoculum. Each dot reports the data from a single animal and black lines 
indicate the median values. The dotted grey line states the lower detectable 
value.  B) CFU counts in kidneys of mice infected with S. aureus sacrificed 
7 days later on. Each dot is referred to a single animal and black lines show 
median values. The dotted grey line states the lower detectable value.  In 
both the cases, statistical analyses were performed with a Mann-Whitney t 
test. 
 
Further analyses were then performed in the attempt to understand 
the possible mechanism(s) of action of the vaccine. To this purpose, 
we analyzed both the humoral and the cellular immune components. 
52 
 
First we measured antibody titres against each single antigen of the 
vaccine in the knee joint washes. In figure 22A IgG titres against all 
the antigens are reported, demonstrating that all of them induced 
seroconversion in immunized animals and that measurable antibody 
levels could be detected in the knee joints.  
Moreover, immune cells were analyzed comparing the results 
obtained for the vaccinated animals to those obtained for the 
negative controls. Fewer dead cells were found in knee joint washes 
of combo-immunized mice and, even if the number of total cells 
recovered was more or less the same in both the samples, the 
number of neutrophils recruited was lower in the immunized group 
indicating the lower state of general inflammation (fig.22B). 
Interestingly, B cells were preserved in knee joints after immunization 
with protein combo as if the vaccination could increase the number of 
cells recruited and/or shield them from S. aureus mediated toxicity 
(fig. 22B). 
Cytokine levels were also measured in this site. Even if none of the 
analyzed mediators significantly changed between the 2 groups, it 
was interesting to note that almost all the pro-inflammatory cytokines 
(like IL-1, IL-1, and G-CSF) were a little less in knee joint washes 
of combo immunized animals in respect to mocked immunized mice 
(fig. 22C), confirming the observation already done of a general lower 
state of inflammation of treated animals. 
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Figure 22. IgG titres, immune cells recruitment and cytokines analysis 
of immunized mice. A) IgG titres of combo antigens from knee joint 
washes of mice immunized with alum or combo/alum and infected with S. 
aureus Newman strain. Mean Fluorescence Intensity (MFI) was used as 
titer and box-whiskers analysis (median plus 25 and 75 percentile) of row 
data was reported.  Statistical analysis was performed with a Mann-
Whitney t test. B) Immune cell recruitment in knee joint washes of mice 
immunized and infected with S. aureus 7 days after infection. Fold change 
in respect to the basal situation (median of naïve mice for each cellular 
subset) was plotted, medians and interquartile range were reported. N= 
Neutrophils, Mo= Monocytes, Ma= Macrophages, DC= Dendritic cells, B= B 
cells, CD4+= CD4+ T cells, CD8+ =CD8+ T cells. Statistical analysis was 
performed with a Mann-Whitney t test. Only statistically significant 
differences were reported. C) Cytokine analysis of knee joint washes from 
mice immunized with alum or combo/alum and infected with S. aureus 
Newman strain. Data were reported in pg/ml and only the cytokines from a 
panel of 23 mediators analyzed which were measurable were shown. 
Medians and interquartile range were reported and statistical analysis was 
performed with a Mann-Whitney t test. Only statistically significant 
differences were shown. 
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3 Discussion 
In the present work we set a new, long lasting and reproducible 
mouse model of S. aureus mediated arthrosynovitis-osteomyelitis 
that allowed us to unravel the host immune response during these 
pathologies. Using this model we were also able to demonstrate that 
the Novartis proposed Vaccine against staphylococcal infections 
overcame the activity of a commercial antibiotic in reducing bacterial 
load in knee joints. High IgG titres against all the vaccine 
components were found  in knee joint washes of vaccinated animals 
one week after infection with S. aureus Newman strain. Moreover, 
vaccination seemed to preserve the immune cells recruited in joints 
after infection by bacteria-mediated killing and this was particularly 
clear for B cells. Finally, a lower degree of general inflammation was 
observed in knee joints of vaccinated animals as compared to the 
controls that reflected a lower recruitment of neutrophils in situ.  We 
can conclude that this vaccine could become a powerful tool for 
preventing S. aureus-mediated arthrosynovitis and osteomyelitis in 
humans, pathologies that still have often poor outcomes.  
Septic arthrosynovitis and osteomyelitis are severe and painful joints 
and bones diseases often associated with treatment failure and poor 
prognosis. Most of these pathologies are due to Staphylococcus 
aureus  that is also responsible for the ones with the highest 
complications (67). 
55 
 
Since the pathophysiology of these diseases is not completely 
understood, the use of animal models has proven invaluable for 
studying them as well as for testing the efficacy of experimental 
preventive and therapeutic treatments (68). To mimic the human 
disease as closely as possible, several features of the host bacterium 
relationship should be clarified. During the past decades, the use of 
experimental models of staphylococcal infections was useful to 
understand the involvement of several bacterial virulence factors as 
well as the host response to the bacterial infection.  Dogs, rabbits, 
rats, chickens, and mice (69,70,71,72,73) have been used to develop 
Staphylococcus aureus model of arthrosynovitis and osteomyelitis, 
but it is believed that the mouse model is optimal because of the 
resemblances between the murine and the human immune and 
inflammatory systems.  
Nevertheless, the existing animal models generally study 
osteomyelitis and arthritis like two different diseases but since these 
pathologies often coexist in humans, they do not completely reflect 
the full scenario of the natural disease. Moreover, most of them focus 
only on the acute phase of the disease while the chronic phase, 
which occurs later on during the infection, is often the most 
debilitating one (74,75). Recently Horst et al. developed a novel 
hematogenous murine model of acute and chronic osteomyelitis, but 
the immune response induced has not been analyzed neither locally 
nor systemically (72).  
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Based on this background, we thought it would be important to have 
a consistent model of osteomyelitis and arthritis established in mice 
after infection with S. aureus, which would allow to study both the 
acute and chronic phases, dissecting the humoral and cellular host 
immune response locally and systemically, and to evaluate the 
efficacy of therapeutic and preventive tools.   
An important issue was how the staphylococci spread through the 
body to reach the joints. The most common routes of infection for 
both septic arthritis and osteomyelitis in humans are the 
haematogenous, the contiguous, or the direct ones (13, 14, 15, 16, 
17), but  it was clearly shown that most of bacterial joint infections in 
humans are caused by bacteria which spread hematogenously (18).  
Thus we decided that intravenous (i.v.) inoculation of bacteria 
mimicking the hematogenous route of infection would be the optimal 
delivery route for the animal model that we wanted to set up. Indeed 
after inoculum, bacteria are required to adapt to the environment 
within the host, to survive bactericidal components in the blood, 
disseminate to synovial tissue and penetrate various structures to 
reach the joint space (69) being in this way really similar to what 
happens during natural infections in humans.  
 
We reported in figure 5 using the In Vivo Imaging System (IVIS®) that 
S. aureus showed a particular tropism for bones and joints 
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considering its ability to quickly and long lastingly colonize these 
tissues. This was somehow expected since S. aureus expresses 
several receptors (adhesins) specific for bone matrix components 
such as fibronectin (76), collagen (77) and bone sialoprotein (78). 
Once reached the joints S. aureus was able to cause both 
arthrosynovitis and osteomyelitis and the infection lasted for months 
progressing to a chronic phase (figures 7, 10A and 11). Interestingly, 
only combining histopathological and microbiological analysis of both 
the in situ and the systemic situation we were able to clearly identify 
an acute and a chronic phase of arthrosynovitis and osteomyelitis. 
On the one hand CFU decrease in the knee joints and kidneys 
seemed to push toward the resolution of the pathology, but on the 
other hand the rise of CFU in the blood and, in particular, the 
increase in age grade and severity of histopathological analysis of 
knee joints showed a completely different scenario. The acute phase 
was therefore characterized by a high bacterial burden in joints and 
kidneys, but medium level of severity of the lesions in the knee joints, 
while when the infection became chronic, CFU numbers decreased, 
as the host immune system was able to control bacteria, but the 
severity of the lesions dramatically increased with destruction and 
deformation of the bone architecture, and bacteria used again the 
blood as vehicle for further dissemination. Taken together, these data 
allowed us in defining the two distinct phases of infections, an acute 
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phase that picks from 7 to 14 days after inoculum, and a chronic 
phase, that could be clearly seen at the latest time point.  
Like in humans, the acute phase was shown to be highly 
symptomatic and was characterized by a particularly active immune 
response. 
Interestingly, the host immune response, both humoral and cellular, 
seemed to be quite different between blood and knee joints indicating 
that a specific immune response is built up against this pathogen in 
situ. While in the blood the situation was quite complicated probably 
representing  a multi-organ infection, during this phase all the pro-
inflammatory cytokines (like IL-1β, IL-6 and IL12p40) peaked in the 
knee joints between 7 and 14 days after infection, reflecting the 
profile observed for CFU counts and allowing the recruitment of the 
cellular components of the host immune response. Moreover, a good 
correlation between some of the cytokines we analyzed and CFU 
counts in knee joints was observed (figure 15). This important finding 
could pave the way for using new potential biomarkers for humans, 
that could be not only useful in the specific diagnosis of the diseases, 
but above all to define the degree of severity and the maturation of 
disease, helping to figure out the possible prognosis and to give the 
most proper and accurate care for a patient.  
As expected, IgM and IgG levels rose significantly early during the 
acute phase indicating that a strong adaptive immune response was 
mounted against the pathogen really soon and that the inflammation 
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state of the joints was useful in allowing the diffusion of antibodies 
and the recruitment of plasmacells in situ. But inflammation means 
also cellular recruitment. We therefore approached the cellular 
analysis both in the knee joints and in the blood using, in our 
knowledge for the first time in these models, a flow cytometer 
analysis with a specific staining for different immune cells. This 
approach allowed us analyzing almost all the possible immune cells 
recruited in this site at the same time. 
Both myeloid and lymphoid cells were rapidly and strongly recruited 
in situ. Monocytes and macrophages increased between 10 and 20 
fold starting immediately after infection. These cells play an important 
role in controlling initial stages of infection not only directly through 
the phagocytosis of the bacteria, but also producing chemoattractant 
molecules for neutrophils recruitment. Their role in the early stages of 
infection is in any case controversial.  Verdrengh et al. (79) indeed 
studied the role of these cells in staphylococcal arthritis using 
monocytopenic mice. During the time these mice exhibited a 
significantly less severe arthritis than the control animals and this 
was accompanied by decreased serum levels of the proinflammatory 
cytokines TNFα and IL-6. In contrast, infection-triggered mortality 
was increased in the monocytopenic mice as compared with the 
control animals. Notably, the monocytopenic mice exhibited elevated 
bacterial burden in the blood and kidneys. This study indicated a dual 
role of mononuclear phagocytes in the pathogenesis of S. aureus-
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induced infection. On the one hand, absence of macrophages led to 
a favorable outcome concerning the severity of arthritic lesions, but 
on the other hand the direct and indirect clearance of bacteria 
mediated by monocytes/macrophages was decreased, resulting in 
poor survival. Neutrophils were actually the population which showed 
the highest increment among all the cells changing almost 1000 fold 
as compared to not infected mice. This increment was evident in the 
blood too, even if less impressive, probably suggesting a greater 
production due to an increased demand from other tissues and 
organs. It is not strange to see that neutrophils were strongly 
recruited in the knee joints immediately after infection peaking at 14 
days, since it had been already demonstrated that they played an 
essential role in controlling bacterial spreading in these kinds of 
infections. Indeed mice depleted of these cells died in a few days 
after infection with S. aureus and showed more severe signs of 
arthritis, increased bacterial burden in blood and kidneys and 
exhibited increased levels of the proinflammatory cytokines TNFα, IL-
6, and INFγ, reflecting the severity of their disease (80,81).  
The role of T cells in arthrosynovitis and osteomyelitis was already 
reported by Abdelnour et al. (82) who showed using a immune-
histochemical approach an increase of these cell populations in the 
joints between 3 and 14 days after the bacterial inoculum. We 
confirmed their findings but our approach was certainly more suitable 
for studies where a large number of animals and multiple analyses 
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were required. During the first days after infection circulating 
lymphoid cells left the blood spreading into tissues where they were 
recruited by the presence of infective agents. Interestingly, while 
CD4+ and CD8+ cells incremented in the knee joints from day 3 to 
day 14 confirming our hypothesis, this was not true for B cells whose 
number suddenly decreased coming back to basal level only 
between day 14 and day 30.  
 
One possible explanation for this behavior is the production by S. 
aureus of protein A (Spa). In recent studies, it was shown that SpA 
has the properties of a B cell superantigen by virtue of interactions 
with a large supraclonal B cell set via high affinity framework-
mediated interactions with soluble and cell-associated B cell 
receptors (BCR, 83). Moreover, other studies demonstrated that a 
domain of SpA forms a complex with human Fab via a 
conformational surface on BCR (84) and that this target is conserved 
among amphibian, avian, and mammalian species (85). 
SpA toxic activity in vivo was already demonstrated by Goodyear et 
al. who injected in mice purified protein A and then followed the fate 
of peripheral B cells expressing BCRs with VH regions capable of 
binding SpA. They observed a rapid down-regulation of BCRs and 
the coreceptors CD19 and CD21, the induction of an activation 
phenotype, and limited rounds of proliferation. Apoptosis followed 
through a process heralded by the dissipation of mitochondrial 
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membrane potential, the induction of the caspase pathway, and DNA 
fragmentation (86). This apoptotic collapse is of course a key 
mechanism that suppresses adaptive immune responses during 
staphylococcal infection playing an essential role for S. aureus 
escaping of host immune system. In our knowledge we reported for 
the first time that S. aureus is able to kill B cells during an infection in 
a mouse model even if we cannot exclude that  other bacterial 
proteins could be, together with protein A, in part responsible for this 
phenomenon. Nevertheless S. aureus could also reduce B cells in 
situ through indirect mechanisms, such as inhibiting host factors that 
recruit those cells directly in the sites where they are requested. 
Further investigations are required to unravel these open questions 
and to better explain the phenomenon we reported here. 
The chronic phase was characterized by a general lower 
inflammation state in the knee joints as compared to the acute one, 
even if the severity of the lesions significantly increased. The 
cytokines profile in situ came back to basal level trailing behind also 
the number of cells. The lower inflammation was also highlighted by 
the decrease in antibody titres as if the remained S. aureus colonies 
could hide themselves to the host immune system. In fact Horst et al. 
demonstrated that S. aureus could form microcolonies within the 
nonmineralized collagen matrix or locate intracellularly within 
neutrophils (72). In the blood there seemed to be a restoring of the 
normal situation regarding the cell populations, but the cytokines 
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revealed the presence of a more complicated situation.  Indeed, 
while some pro-inflammatory cytokines  remained high throughout all 
the observation time (TNFα, GM-CSF, MIP-1β) showing a permanent 
state of inflammation, some others clearly declined during the last 
time points (IL-6, IL-1β, KC). This behavior could probably be 
partially explained by the presence of high level of anti-inflammatory 
cytokines secreted to control the activity of the inflammatory ones.       
 
The model of S. aureus mediated arthrosynovitis and osteomyelitis 
we proposed is suitable for testing both preventive and therapeutic 
tools against this pathogen. Correlates of protection could also be 
found using such approach that will be useful for further development 
of vaccines and new antibiotics.  
The proposed Novartis vaccine against S. aureus-mediated 
infections that we tested in this study demonstrated not only to be 
protective against this pathogen, but also to be more effective than 
an ampicillin treatment in reducing CFU infiltration in knee joints. As 
reported elsewhere (14) antibiotics even if effective in eradicate 
bacteria in multiple organs and tissues, often fail when pathogens 
reach joints and bones, probably because of the particular nature of 
these tissues (i.e. poor blood supply). For this reason, an effective 
vaccine against S. aureus joints and bones pathologies is of great 
interest. When mice were immunized with the S. aureus combo 
vaccine adjuvanted with alum phosphate, a reduction in CFU counts 
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both in kidneys and knee joints was observed. Similar results could 
be also obtained in kidneys with two injection of ampicillin, but this 
antibiotic was completely inefficacious against bacteria in knee joints. 
High antibodies titres against all the components of the protein 
combo could be detected in the knee joints lavages and this could 
partially explain the efficacy of this vaccine (fig 22_A). Fewer dead 
cells could be detected in the site when animals were vaccinated as 
compared to not vaccinated or antibiotic treated animals highlighting 
the power of the vaccine in reducing S. aureus mediated cellular 
toxicity.   Moreover, a lower degree in general inflammation could 
also be detected, since less neutrophils were recruited after infection 
in vaccinated animals (fig.22_B). This was also evident when 
proinflammatory cytokines were analyzed in vaccinated and not 
vaccinated mice (fig.22_C). Most of them resulted indeed slightly 
reduced in treated animals as compared to controls. Finally, B cell 
number seemed to be restored in vaccinated animals, but this was 
also evident for the antibiotic treatment. In this case, probably, a dual 
role was played. On the one hand systemic protection of immune 
cells against S. aureus toxicity allowed more B cells to survive and to 
migrate to the tissues and organs where they are requested. On the 
other hand, local protection against toxicity resulted in a lower killing 
of B cells. These two aspects could be both present in the vaccinated 
animals where bacterial reduction in situ resulted in a lower local 
toxicity, while in mice treated with ampicillin only the systemic 
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component should be responsible for the final outcome. It is in any 
case difficult to dissect the relative contribution of the two 
components.  
The Novartis vaccine mechanism of protection is nevertheless not 
completely unraveled. Further analyses are for example necessary 
for dissecting CD4+ T cells and neutrophils activities. On the basis of 
the results we have already obtained, we showed that CD4+ T cell 
recruitment did not significantly changed among vaccinated, not 
vaccinated and antibiotic treatment, but we did not still analyzed the 
specific Th pathways of the different groups. Moreover, activation 
patterns of neutrophils in the different groups could also be of interest 
in trying to find new possible correlates of protection. 
In summary, we described a murine model of S. aureus 
hematogenous arthritis/osteomyelitis that mimics most of the aspects 
of the human disease including the different clinical phases and the 
host immune response. Moreover we used this mouse model to test 
and prove the protection led by Novartis proposed combo vaccine 
against these diseases and to unravel the induced mechanism of 
protection. This model provides an important tool for microbiological 
and other immunological studies on bone and joint infections and for 
the evaluation of novel approaches for vaccine, diagnostics and 
therapeutic treatments. 
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        4 Material and Methods  
4.1 Bacterial strains 
Staphylococcus aureus Xen36 was derived from the parental strain 
Staphylococcus aureus ATCC 49525 (Wright), a clinical isolate from 
bacteremia patient. S.aureus Xen 36 possesses a stable copy of the 
modified Photorhabdus luminescens luxABCDE operon at a single 
integration site on a native plasmid (87). 
Staphylococcus aureus  Xen8.1 was derived from the parental strain S. 
aureus 8325-4. S. aureus Xen8.1 was engineered through transposition of 
Tn4001luxABCDE on plasmid pXen-5. Xen8.1 possesses a single stable 
copy of the modified P. luminescens lux operon that was inserted in the δ-
toxin coding region in the RNAIII transcript downstream of the agr P3 
promoter on chromosome (88). 
Staphylococcus aureus Xen29 was derived from the parental strain S. 
aureus 12600, a pleural fluid isolate, which is also designated as 
NCTC8532. S. aureus Xen29 possesses a stable copy of the modified 
Photorhabdus luminescens lux ABCDE  operon at a single integration site 
on the bacterial chromosome (89,90). 
S. aureus strain Newman was isolated in 1952 from a human infection 
(NCTC8178), originally isolated from a case of secondarily infected 
tubercular osteomyelitis in man and has been used extensively in animal 
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models of staphylococcal disease due to its robust virulence phenotypes 
(91). 
         4.2 Preparation of Bacteria  
An aliquot of Bacteria (2ml) frozen in PBS + BSA 10% w/v + glutamate 
10% v/v is thawed, inoculated in 48 ml of Triptych Soy Broth (starting from 
an optical density of 0.05) and incubated at 37°C in agitation (250 RPM). 
Bacteria were grown until the optical density at 600 nm (OD600), reached 
OD 2 they were washed twice with sterile PBS and centrifuged at 4000 Xg 
for 10 minutes. Bacterial pellet was suspended in PBS in order to obtain 
the desired concentration.  
        4.3 In vivo imaging 
For the 2D in vivo imaging acquisitions, IVIS 100® (Perkin Elmer) was 
used. For 3D in vivo imaging acquisition, The IVIS® SpectrumCT was 
used. After infection with bioluminescent S. aureus Xen 36, Xen 8.1 or  
Xen 29, mice were anesthetized with isofluorane 2.5% and imaged. 
Bioluminescent images were displayed using a pseudocolor scale (blue 
representing the least-intense light and red representing the most-intense 
light) that was overlaid on a gray-scale image to generate a 2D or 3D 
picture of the distribution of bioluminescent bacteria in the animal. The 
acquired image data were saved as two-dimensional arrays containing 
values corresponding to the number of photons contained within each 
pixel. The photon emissions from a region of interest (ROI) were quantified 
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using the Living Image 2.1 software package (Xenogen Corporation), and 
the data are presented as relative light units contained within each region. 
To confirm that the bioluminescence signals corresponded to the bacterial 
burden in vivo, bacteria from knee joint were quantified. The CFU’s 
number of each knee joint was related with its ROI value (photon/second) 
using the Spearman correlation. 
4.4 Histopathology examination 
Histologic examination of hind legs at each time point (time 0, 3, 7, 14, 30 
90 days post infection) was performed after routine fixation, 
decalcification, paraffin embedding, and staining with hematoxylin and 
eosin. Severity and age grade of arthritis/osteomyelitis were assessed by 
a blinded experienced pathologist analyzing different features of joint and 
bone diseases (exudate, synovitis, pannus formation, cartilage,  bone 
destruction and deformation, abscesses formation, presence of different 
characteristic cells) and each slide was graded using a specific scale.  
4.5 Immunohistochemistry 
Immunohistochemical analysis on 4-µm knee joints sections was 
performed by using Ventana Benchmark® XT autostainer: primary Anti-
Staphylococcus aureus antibody conjugated with biotin (ab68954) was 
diluted 4.5 mg/ml in PBS+BSA 3% and incubated overnight. Negative 
control slides without primary antibodies were included for each staining. 
High ionic strength protein blocking solution for reduction of background 
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was used (Antibody Block Ventana 760-4204). For the antibody detection 
the DISCOVERY® RedMap Kit (RUO 760-123 250) was used. 
4.6 Confocal microscopy 
To verify bacterial localization, knee joints of mice infected with 2x106 CFU 
of S. aureus and sacrificed one week later, were frozen and then cut using 
cryostat. Samples were fixed in 2% paraformaldehyde (PFA) for 20 min at 
room temperature (RT) and then washed three times with a permeabilizing 
solution containing Bovin Serum Albumin (3%) and Saponin (1%). 
The antibody mix solution, composed by anti-osteocalcin (goat) final 
dilution 1:250, and anti S. aureus (rabbit) final dilution 1:200 (both by 
Abcam) was used to detect the bone and S. aureus cells respectively. 
After 1 h of incubation, the mix with secondary antibodies was added to 
the knee slide. This mix was composed by chicken anti-goat conjugated 
with ALEXA FLUOR 647 (far red) final dilution 1:200 to stain osteocalcin, 
by goat anti-rabbit conjugated with ALEXA FLUOR 488 FITC (green)  final 
dilution 1:200 to stain S. aureus cells, and by phalloidin, final dilution 
1:300, conjugated with ALEXA FLUOR 568 (red). Secondary antibodies 
were incubated for 50 min at room temperature (RT).  
Samples were washed three times with the permeabilizing solution (BSA 
3% and saponin 1%), two times with PBS and two times with water. 
Slides were mounted using Mounting medium with DAPI (Life 
Technologies) and incubated over night at RT. 
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Images were obtained using a Zeiss LSM 700 confocal microscope (Carl 
Zeiss). 
 
        4.7 Immunization protocol 
Five-week-old CD1 mice were immunized intramuscularly with a prime-
boost injection (50ul x2) of purified recombinant antigens (10 µg each 
antigen) adsorbed to aluminum hydroxide adjuvant (alum, 2 mg/mL) in 14 
day interval. Control mice received equal amounts of phosphate-buffered 
saline (PBS) and alum adjuvant. Animals were bled immediately prior to 
the first immunization, after each immunization and 7 days after the 
infection, and serum samples and knee joint washes were collected. 
 4.8 Antibiotic treatment  
Pathogen free CD-1, 8 weeks old female mice were infected with Newman 
strain 1/2 x106 via lateral tail vein. 24 and 48 hours after the inoculum mice 
were treated intraperitoneally with Ampicillin 100 µg/g of body weight, or 
with PBS (control group).  
4.9 Mice and infection model 
Pathogen free CD-1, 8 weeks old female mice were purchased from 
Charles River. Mice were inoculated with S. aureus in 100 µL of PBS via 
lateral tail vein. At each time point blood, kidneys, and hind legs were 
collected, to perform histological staining, CFU’s counting, IgG, IgM, 
cytokines measurement and multiparameter immune cell flow cytometry. 
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Mice were monitored on a daily basis and euthanized for humane reasons 
when they exhibited defined endpoints that had been pre-established for 
these studies in agreement with the Novartis Animal Welfare Policies. 
Animal protocols were approved by the Novartis Animal Ethical 
Committee, Siena, Italy, and the Italian Ministry of Health, Rome, Italy. At 
each time point 6 mice were sacrificed, 2 of them were dedicated to 
histology. Kidneys were homogenized using “ gentleMACS™ Dissociator “ 
and plated in several dilution on TSB plates.Legs were dissected and 
muscles excised in order to expose the knee joint. In the joint, between the 
femur and the tibia, a cut is made with a scalpel. Several washes of this 
site are performed in 2 ml of RPMI. Suspensions are filtered using a 70 
µm nylon mash (Becton Dickinson). An aliquot of these joint washes is 
used to count CFU, plating it on TSA plates in several dilutions. Blood was 
collected in presence of heparin (50U/ml). An aliquot is used to count the 
CFU’s number, plating it on TSA plates in several dilutions and 50 µL were 
lysed (BD Pharm Lyse™), for Flow cytometry staining. 
        4.10 Antibodies measurements 
At each time point of observation serum samples and knee joint washes 
were examined for IgG and IgM antibodies directed against Hla purified 
antigen using the Luminex technology. Specifically, 20 μg of recombinant 
protein was coupled to the carboxyl groups of 2.5 million MicroPlex 
microspheres (Luminex Corp), according to the manufacturer's 
instructions. The coupling reaction was confirmed by incubating 5,000 
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antigen-coupled microspheres with eight serial twofold dilutions of a 
hyperimmune antiserum used as a reference. To determine serum titers, 
the beads were incubated with mouse specific sera (dilution 1:10,000 in 
PBS), washed twice in 200 μl of PBS, and then incubated with 
phycoerythrin-conjugated secondary antibodies (1:200; Jackson 
ImmunoResearch) for 15 min in a dark room onto an orbital shaker. 
IgG measurements were determined on the Luminex 200 analyzer using 
Bio-Plex Manager 5.0 software (Bio-Rad, Hercules, CA). Tests were 
performed in duplicate, and the mean fluorescence intensity (MFI) was 
determined. The limit of quantification (LOQ) of the assay was determined 
at an MFI of 100 and was considered the threshold for positive results. 
        4.11 Cytokine analysis 
Joint washes supernatants and serum samples were collected at different 
time points post infection and cytokine concentrations were measured by 
multiplex-bead ELISA (Bioplex, BioRad) according to manufacturer's 
instruction using the mouse 23-plex panel.  
The cytokines analyzed were IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, 
IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN-
γ, KC, MCP-1, MIP-α, MIP-1β, RANTES and TNF-α. 
4.7 Flow Cytometry staining 
Filtered joint washes, and blood were centrifuged (300 Xg, room 
temperature, 5’). Cell pellets were suspended in 100 µl of PBS and 
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transferred in 96 wells round bottom plate. Cells were washed twice in 
PBS (1200 RPM, room temperature, 5’) and treated with PBS + 
CD16/CD32 (FcγIII/II Receptor) to saturate aspecific binding sites and 
incubated 20’, in the dark at room temperature. Cells were stained with 
combinations of the following antibodies: Ly6g PE, CD11B APC, CD11C 
APC fluor 780, MHC II Alexa fluor 700, F4/80 V450,LY6C FITC, CD3 PE 
Cy7, CD19 PECy5, CD4 V500, CD8 PE TEXAS RED, CD335 PERCP Cy 
5.5. Antibodies mix solution, prepared in PBS was added at each sample 
and incubated 20’, in the dark at 4°C. 150 µl of PBS is added at each 
sample and centrifuged (300 XG, 4°C, 5’), two times. 100 µl of CITOFIX is 
added at each sample and incubated 30’, in the dark at 4°C. 150 µl of PBS 
is added at each sample and centrifuged (350 XG, 4°C, 5’), twice. Cell 
pellets were suspended in 200 µl PBS/BSA(1%). The stained cells were 
analyzed using FACS LSR II SOS (special order system, BD) using Flow 
Jo software 9.3.3 (BD Bioscience). 
4.8 Statistical analysis  
Statistical analysis were performed using Graph Pad Prism 5 . Wilcoxon-
Mann-Whitney test (two tailed) or Spearman, for correlation analysis, were 
used to calculate statistical significance. 
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